QUANTRO Therapeutics GmbH

QUANTRO Therapeutics is a leading entity committed to the discovery and development of innovative therapeutics targeting transcription factors in cancer and other diseases. Founded in 2019 as a spin-off of the Institute of Molecular Biotechnology (“IMBA”) and the Research Institute of Molecular Pathology (“IMP”), both situated in Vienna, Austria, QUANTRO bases its operations in Austria. The company's primary aim is to assemble an advanced drug-discovery pipeline leveraging time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates that interfere with transcriptional regulators. The initial focus of QUANTRO lies in cancer-associated transcription factors, which have previously been unresponsive to pharmacologic intervention. Within the Biotechnology and Pharmaceutical industries, QUANTRO stands out as an innovative player in the endeavor to revolutionize disease treatment and management. With its pioneering approach and emphasis on unmet needs in medical science, QUANTRO serves as a promising prospect for potential investors seeking to contribute to groundbreaking advancements in healthcare.